	US 11,911,402 B2
	Methods of treatment with combinations of cannabidiol and psilocybin
Nitin Anand, Richmond Hill (CA); Michael E. Hoffer, Miami, FL (US); Moiz Rangwalla, Richmond Hill (CA); Andy Mera, Richmond Hill (CA); and Gilberto Iragorri, Richmond Hill (CA)
Assigned to ECP Pharma, Richmond Hill (CA)
Filed by ECP Pharma, Richmond Hill (CA)
Filed on Oct. 12, 2022, as Appl. No. 18/045,843.
Claims priority of provisional application 63/255,191, filed on Oct. 13, 2021.
Prior Publication US 2023/0112459 A1, Apr. 13, 2023
Int. Cl. A61K 31/675 (2006.01); A61K 31/00 (2006.01); A61P 25/28 (2006.01); A61K 31/05 (2006.01)

CPC A61K 31/675 (2013.01) [A61K 31/05 (2013.01); A61P 25/28 (2018.01)]

13 Claims

1. A method for treating brain injuries comprising:

administering to a patient a first dosage of about 100 mg to about 300 mg of cannabidiol (CBD); and

administering to the patient, concomitantly with the first dosage, a second dosage of about 1 mg to about 5 mg of Psilocybin, wherein a ratio between the first dosage of CBD and the second dosage of Psilocybin is about 145:1 to about 155:1, and wherein the treatment is for TBI.